Shanghai Pharma stock option exercise concludes

Shanghai Pharmaceuticals Holding (SSE: 601607) has announced the results of the third exercise period for stock options granted in 2019, as well as the second exercise period for reserved stock options. As of February 13, 2025, employees exercised options to purchase 4,828,870 A-shares, representing 69.21% of the total available under the initial grant. For the reserved options, 231,885 shares were issued, accounting for 30.68% of the available options, before the February 7, 2025 deadline. These issuances resulted in proceeds of RMB 88,899,496.7 and RMB 4,674,801.6, respectively, which the company intends to use for working capital. All unexercised stock options will be cancelled. The new shares are tradable, and the total share capital increased by 389,970 shares.